Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENBETA6890 in Healthy Adults Challenged with ETEC
NCT06896136Phase 1Completed
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in enterotoxigenic Escherichia coli infection comparing VENBETA6890 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Feb 2025; status: completed.
02
Drugs
VENBETA6890
03
Conditions
enterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT06896136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06896136.